News >

Vorinostat Triplet Elicits High Responses in Newly Diagnosed MCL

Lisa Astor
Published: Friday, Aug 30, 2019

Stephen E. Spurgeon, MD, of the Center for Hematologic Malignancies at the Knight Cancer Institute of Oregon Health & Science University in Portland

Stephen E. Spurgeon, MD

The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate (ORR) of 97% and a complete response (CR) rate of 80% in newly diagnosed patients with mantle cell lymphoma (MCL), according to results of a phase I/II study. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x